| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| V P Kontaxakis, B J Havaki-Kontaxaki, P P Ferentinos, K G Paplos, C R Soldato. Switching to amisulpride monotherapy for treatment-resistant schizophrenia. European psychiatry : the journal of the Association of European Psychiatrists. vol 21. issue 3. 2006-10-03. PMID:16531015. |
switching to amisulpride monotherapy for treatment-resistant schizophrenia. |
2006-10-03 |
2023-08-12 |
human |
| V P Kontaxakis, B J Havaki-Kontaxaki, P P Ferentinos, K G Paplos, C R Soldato. Switching to amisulpride monotherapy for treatment-resistant schizophrenia. European psychiatry : the journal of the Association of European Psychiatrists. vol 21. issue 3. 2006-10-03. PMID:16531015. |
the objective of this study was to assess switching to amisulpride (ams) in treatment-resistant schizophrenia. |
2006-10-03 |
2023-08-12 |
human |
| D Roesch-Ely, K Göhring, P Gruschka, S Kaiser, U Pfüller, M Burlon, M Weisbro. Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. Pharmacopsychiatry. vol 39. issue 3. 2006-09-28. PMID:16721703. |
pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. |
2006-09-28 |
2023-08-12 |
Not clear |
| Philip J Tyson, Keith R Laws, Kenneth A Flowers, Agi Tyson, Ann M Mortime. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Psychiatry and clinical neurosciences. vol 60. issue 4. 2006-09-20. PMID:16884450. |
comparisons were done for matched schizophrenia patients who were on antipsychotics with (i) an affinity for multiple receptors (olanzapine, clozapine, quetiapine) versus those that have preferential affinity for dopamine receptors (risperidone, amisulpride); and patients on medication with (ii) a high affinity for serotonin (5ht-2a) receptors (risperidone, olanzapine, clozapine) versus those with a low (or no) affinity for 5ht-2a receptors (quetiapine, amisulpride). |
2006-09-20 |
2023-08-12 |
Not clear |
| Miguel Herrera-Estrella, Rogelio Apiquian, Ana Fresan, Isabel Sanchez-Torre. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study. BMC psychiatry. vol 5. 2006-07-27. PMID:15869707. |
the effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study. |
2006-07-27 |
2023-08-12 |
Not clear |
| Stefan Leucht, Rolf R Enge. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 2. 2006-07-06. PMID:16123745. |
we therefore reanalyzed original patient data from all four pivotal, randomized controlled studies (n = 1205) that compared amisulpride with haloperidol in patients with schizophrenia. |
2006-07-06 |
2023-08-12 |
Not clear |
| Anatoly Kreinin, Dmitri Novitski, Abraham Weizma. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. International clinical psychopharmacology. vol 21. issue 2. 2006-03-28. PMID:16421461. |
amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. |
2006-03-28 |
2023-08-12 |
Not clear |
| Anatoly Kreinin, Dmitri Novitski, Abraham Weizma. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. International clinical psychopharmacology. vol 21. issue 2. 2006-03-28. PMID:16421461. |
in a randomized, double-blind, placebo-controlled cross-over study, 20 clozapine-treated schizophrenia (dsm-iv criteria) inpatients with cih were randomly initially assigned to add-on amisulpride (nine patients; 400 mg/day up-titrated from 100 mg/day over 1 week) or placebo (11 patients). |
2006-03-28 |
2023-08-12 |
Not clear |
| Simon Surguladze, Anita Patel, Robert W Kerwin, Martin Knapp, Michael J Travi. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 4. 2005-07-11. PMID:15866352. |
cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. |
2005-07-11 |
2023-08-12 |
Not clear |
| Simon Surguladze, Anita Patel, Robert W Kerwin, Martin Knapp, Michael J Travi. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 4. 2005-07-11. PMID:15866352. |
the aim of the study was to examine the costs of schizophrenia treatment using the atypical antipsychotic amisulpride relative to treatment with other antipsychotics. |
2005-07-11 |
2023-08-12 |
Not clear |
| Simon Surguladze, Anita Patel, Robert W Kerwin, Martin Knapp, Michael J Travi. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 4. 2005-07-11. PMID:15866352. |
amisulpride treatment may lead to a reduction in the cost of treating schizophrenia in comparison with treatment with other antipsychotic medications. |
2005-07-11 |
2023-08-12 |
Not clear |
| Eduard Vieta, Salvador Ros, José Manuel Goikolea, Antonio Benabarre, Ekaterina Popova, Mercè Comes, Jorge Capapey, José Sánchez-Moren. An open-label study of amisulpride in the treatment of mania. The Journal of clinical psychiatry. vol 66. issue 5. 2005-07-11. PMID:15889942. |
amisulpride is a selective d(2)-d(3) antagonist that has been reported to be effective in the treatment of schizophrenia and major depressive disorder. |
2005-07-11 |
2023-08-12 |
Not clear |
| Judit Harangozó, Adrienn Slezák, Balázs Kukla, Kinga Borsos, Orsolya Német. [Costs related to change to amisulpride in patients suffering from schizophrenia]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 6. issue 3. 2005-05-24. PMID:15816302. |
[costs related to change to amisulpride in patients suffering from schizophrenia]. |
2005-05-24 |
2023-08-12 |
Not clear |
| Judit Harangozó, Adrienn Slezák, Balázs Kukla, Kinga Borsos, Orsolya Német. [Costs related to change to amisulpride in patients suffering from schizophrenia]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 6. issue 3. 2005-05-24. PMID:15816302. |
the present research studied the cost effects of converting patients suffering from schizophrenia to the use of amisulpride, in order to learn whether the relatively higher medicine costs were compensated for under the hungarian economic and financing conditions. |
2005-05-24 |
2023-08-12 |
Not clear |
| Brian Cook, Gerry Hoogenboo. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. vol 12. issue 1. 2005-04-11. PMID:15715745. |
combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. |
2005-04-11 |
2023-08-12 |
Not clear |
| Ingo Vernaleken, Thomas Siessmeier, Hans-Georg Buchholz, Sebastian Härtter, Christoph Hiemke, Peter Stoeter, Frank Rösch, Peter Bartenstein, Gerhard Gründe. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. The international journal of neuropsychopharmacology. vol 7. issue 4. 2005-02-24. PMID:15683553. |
high striatal occupancy of d2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. |
2005-02-24 |
2023-08-12 |
human |
| Robert Göder, Margret Boigs, Sisko Braun, Lars Friege, Gunther Fritzer, Josef Bernd Aldenhoff, Dunja Hinze-Selc. Impairment of visuospatial memory is associated with decreased slow wave sleep in schizophrenia. Journal of psychiatric research. vol 38. issue 6. 2005-02-07. PMID:15458855. |
we studied 17 patients with schizophrenia on stable antipsychotic medication with amisulpride (age range 22-44 years; 7 women) and 17 healthy controls (matched for age, gender and educational level). |
2005-02-07 |
2023-08-12 |
Not clear |
| Kate McKeage, Greg L Ploske. Amisulpride: a review of its use in the management of schizophrenia. CNS drugs. vol 18. issue 13. 2005-02-04. PMID:15521794. |
amisulpride: a review of its use in the management of schizophrenia. |
2005-02-04 |
2023-08-12 |
Not clear |
| Kate McKeage, Greg L Ploske. Amisulpride: a review of its use in the management of schizophrenia. CNS drugs. vol 18. issue 13. 2005-02-04. PMID:15521794. |
amisulpride (200-1200 mg/day) was at least as effective as haloperidol and as effective as risperidone or olanzapine, in studies of up to 1 year in patients with schizophrenia manifesting predominantly positive symptoms. |
2005-02-04 |
2023-08-12 |
Not clear |
| Kate McKeage, Greg L Ploske. Amisulpride: a review of its use in the management of schizophrenia. CNS drugs. vol 18. issue 13. 2005-02-04. PMID:15521794. |
in conclusion, oral amisulpride (200-1200 mg/day) is at least as effective as haloperidol, and as effective as risperidone or olanzapine, in the treatment of patients with schizophrenia manifesting predominantly positive symptoms. |
2005-02-04 |
2023-08-12 |
Not clear |